Drug intelligence / Profile preview

pctx-1

Development stage
Preclinical
Lead developer
Institut de Pharmacologie Moléculaire et Cellulaire
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Laboratory Use (injection In Research Settings)
01

Overview

**PcTx-1** (psalmotoxin 1) is a 40-amino acid peptide toxin derived from the venom of the Trinidad tarantula *Psalmopoeus cambridgei*. It is a member of the inhibitor cystine knot (ICK) peptide family, featuring three disulfide bonds stabilizing a compact structure comprised mainly of a three-stranded antiparallel β-sheet and multiple loops. PcTx-1 is the first identified and most potent **selective blocker** of the acid-sensing ion channel 1a (**ASIC1a**), a proton-gated sodium channel implicated in pain perception (nociception), synaptic plasticity, learning, and memory. PcTx-1 binds to the extracellular domain of ASIC1a, increasing its apparent affinity for protons and thereby inducing chronic desensitization at physiological pH. This mechanism effectively inhibits ASIC1a activity, with potential analgesic and neuroprotective effects shown in preclinical rodent models of acute pain and ischemic stroke. PcTx-1 blocks ASIC1a with high potency (IC50 in the low nanomolar range) and selectivity, and its unique binding surface provides a template for the development of future ASIC-targeted therapeutics[1][5][3][8][9].

Other names
psalmotoxin 1psalmotoxin1psalmotoxin-1π-TRTX-Pc1a
02

Targets

ASIC1a

Beyond the preview

Go deeper on pctx-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pctx-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call